TMCnet News
Research and Markets: Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant PeptidesDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/svdjqf/biosimilars) has announced the addition of the "Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides" report to their offering. The global market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further classified into insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Glucagon and calcitonin are considered under the recombinant peptides segment. The recombinant glycosylated proteins segment is the largest segment of the market with a share of 40% of the global market in 2013. Of all the products, monoclonal antibodies will be the fastest-growing segment at an estimated CAGR of 41.9% from 2013 to 2018. Following this, insulin will be the second-fastest growing market from 2013 to 2018. The growth is attributed to the rise in incidences of diabetes; the ongoing patent expiration of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of biosimilars of inslin. By application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure). Oncology is the largest and fastest-growing segment of the global biosimilars market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyles. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast period (2013 to 2018). The major factors driving the growth of the market are the launch of new biosimilars (monoclonal antibodies, filgrastim, and follitropin); ongoing clinical research on potential pipeline products; patent expirations of various biologics such as Neupogen, Humira, and Lantus; and the increasing demand for first-wave biosimilar products such as somatropin, filgrastim, and erythropoietin. Scope of the Report Product - Recombinant Non-glycosylated Proteins -- Insulin -- Human Growth Hormone -- Granulocyte Colony--stimulating Factor (G--CSF) -- Interferons - Recombinant Glycosylated Proteins -- Erythropoietin -- Monoclonal Antibodies -- Follitropin - Recombinant Peptides -- Glucagon -- Calcitonin Service - Contract Manufacturing Organizations (CMO) - Contract Research Organizations (CRO) - Others (Bioinformatics and Sales & Marketing Services) Application - Oncology - Blood Disorders - Chronic & Autoimmune Diseases - Growth Hormone Deficiency - Infectious Diseases - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Analysis 6 Global Biosimilars Market, By Product 7 Global Biosimilars Market, By Application 8 Global Biosimilars Service Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/svdjqf/biosimilars |
